Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Background Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate the efficacy of niraparib versus placebo as maintenance treatment for patients with platinum-sensitive, rec...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, Amit M. Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A. Ledermann, Domenica Lorusso, Ignace Vergote, Noa Ben-Baruch, Christian Marth, Radosław Mądry, René dePont Christensen, Jonathan S. Berek, Anne Dørum, Anna V. Tinker, Andreas du Bois, Antonio González-Martı́n, Philippe Follana, Benedict B. Benigno, Per Rosenberg, Lucy Gilbert, B.J. Rimel, Joseph Buscema, John Balser, Shefali Agarwal, Ursula A. Matulonis
Format: Artigo
Idioma:anglès
Publicat: 2016
Accés en línia:https://doi.org/10.1056/nejmoa1611310
https://www.nejm.org/doi/pdf/10.1056/NEJMoa1611310?articleTools=true
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Internet

https://doi.org/10.1056/nejmoa1611310
https://www.nejm.org/doi/pdf/10.1056/NEJMoa1611310?articleTools=true

Ítems similars